See more : Wuchan Zhongda Geron Co.,Ltd. (002722.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Aurora Cannabis Inc. (ACB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aurora Cannabis Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Sustainable Green Team, Ltd. (SGTM) Income Statement Analysis – Financial Results
- Ginwa Enterprise (Group) Inc. (600080.SS) Income Statement Analysis – Financial Results
- Tekkorp Digital Acquisition Corp. (TEKK) Income Statement Analysis – Financial Results
- Jufan Industrial Co., Ltd. (4584.TWO) Income Statement Analysis – Financial Results
- Houston American Energy Corp. (HUSA) Income Statement Analysis – Financial Results
Aurora Cannabis Inc. (ACB)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.auroramj.com
About Aurora Cannabis Inc.
Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 270.28M | 233.29M | 221.34M | 245.25M | 278.91M | 247.94M | 55.20M | 18.07M | 1.44M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40.83K | 0.00 | 0.00 |
| Cost of Revenue | 138.82M | 297.65M | 200.11M | 266.81M | 312.45M | 88.12M | 11.68M | 2.01M | 763.00K | 304.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 131.46M | -64.36M | 21.23M | -21.56M | -33.54M | 159.82M | 43.52M | 16.06M | 676.27K | -304.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40.83K | 0.00 | 0.00 |
| Gross Profit Ratio | 48.64% | -27.59% | 9.59% | -8.79% | -12.03% | 64.46% | 78.84% | 88.87% | 46.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 3.57M | 6.56M | 10.39M | 11.45M | 26.07M | 14.78M | 1.68M | 314.00K | 565.14K | 432.38K | 307.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 104.94M | 68.22M | 126.97M | 139.68M | 265.18M | 279.40M | 80.42M | 14.40M | 3.93M | 2.61M | 280.67K | 152.64K | 250.02K | 181.96K | 49.99K | 185.35K | 0.00 | 0.00 |
| Selling & Marketing | 51.94M | 51.97M | 62.03M | 55.20M | 91.27M | 99.29M | 29.45M | 10.27M | 1.71M | 1.02M | 248.21K | 142.94K | 61.27K | 18.97K | 7.20K | 0.00 | 0.00 | 0.00 |
| SG&A | 156.88M | 183.40M | 188.99M | 194.88M | 356.45M | 378.69M | 109.86M | 24.67M | 5.63M | 3.63M | 280.67K | 295.59K | 311.29K | 200.93K | 57.18K | 185.35K | 228.56K | 1.25K |
| Other Expenses | 1.67M | 0.00 | -21.59M | 6.13M | -28.64M | -3.26M | -907.00K | -1.14M | 593.22K | -5.06M | 25.82K | 107.29K | 19.50K | 409.00 | 583.00 | 834.00 | 490.00 | 0.00 |
| Operating Expenses | 158.54M | 189.96M | 240.60M | 225.09M | 450.93M | 456.84M | 123.63M | 25.70M | 6.79M | 4.37M | 306.49K | 402.88K | 330.79K | 201.33K | 57.77K | 186.18K | 229.05K | 1.25K |
| Cost & Expenses | 297.36M | 487.61M | 440.71M | 491.90M | 763.38M | 544.97M | 135.30M | 27.71M | 6.03M | 4.37M | 306.49K | 402.88K | 330.79K | 201.33K | 57.77K | 186.18K | 229.05K | 1.25K |
| Interest Income | 12.81M | 19.00M | 4.51M | 5.75M | 4.99M | 3.68M | 2.51M | 861.00K | 72.78K | 27.64K | 7.86K | 9.39K | 15.03K | 15.56K | 14.35K | 40.83K | 0.00 | 0.00 |
| Interest Expense | 14.19M | 39.46M | 71.81M | 66.44M | 77.54M | 41.03M | 2.28M | 1.29M | 619.12K | 177.41K | 101.08K | 9.39K | 15.03K | 745.00 | 484.00 | 310.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 33.07M | 43.57M | 93.66M | 98.08M | 114.89M | 88.26M | 12.26M | 1.09M | 593.22K | 304.80K | 303.00 | 432.00 | 422.00 | 409.00 | 583.00 | 834.00 | 490.00 | 0.00 |
| EBITDA | 20.47M | -210.74M | -143.09M | -137.20M | -393.23M | -214.66M | -78.46M | -12.98M | -4.75M | -9.24M | -298.33K | -402.45K | -330.36K | -185.36K | -57.18K | -144.52K | -228.56K | -1.25K |
| EBITDA Ratio | 7.58% | -90.34% | -64.65% | -55.94% | -140.99% | -86.58% | -142.14% | -71.86% | -329.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -353.91% | 0.00% | 0.00% |
| Operating Income | -46.45M | -254.32M | -231.45M | -282.82M | -490.96M | -314.24M | -95.77M | -11.19M | -4.59M | -4.37M | -306.49K | -402.88K | -330.79K | -202.08K | -58.25K | -145.35K | -229.05K | -1.25K |
| Operating Income Ratio | -17.19% | -109.01% | -104.57% | -115.32% | -176.03% | -126.74% | -173.51% | -61.95% | -318.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -355.95% | 0.00% | 0.00% |
| Total Other Income/Expenses | -31.15M | -41.10M | -1.43B | -392.46M | -2.83B | 6.14M | 168.08M | -1.90M | 89.08K | -5.06M | -93.22K | 9.39K | 15.03K | -167.26K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -59.60M | -295.42M | -1.72B | -699.80M | -3.38B | -328.23M | 77.33M | -17.26M | -5.87M | -9.73M | -399.71K | -393.49K | -315.76K | -353.77K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -22.05% | -126.63% | -777.14% | -285.34% | -1,213.27% | -132.38% | 140.09% | -95.56% | -408.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -554.00K | -20.32M | -2.14M | -6.32M | -83.40M | -30.31M | 8.10M | -4.30M | -148.84K | -207.71K | 7.86K | 0.00 | 0.00 | -31.28K | -13.86K | 310.00 | -51.76K | -1.27K |
| Net Income | -69.33M | -265.33M | -1.72B | -693.63M | -3.31B | -290.84M | 71.94M | -12.97M | -5.72M | -9.52M | -399.71K | -393.49K | -315.76K | -322.50K | -43.91K | -145.66K | -177.29K | 1.27K |
| Net Income Ratio | -25.65% | -113.73% | -776.02% | -282.82% | -1,186.90% | -117.30% | 130.33% | -71.78% | -397.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -356.71% | 0.00% | 0.00% |
| EPS | -1.46 | -8.22 | -7.99 | -41.01 | -342.14 | -435.59 | 1.88 | -0.56 | -0.53 | -1.48 | -0.30 | -0.29 | -0.24 | -0.24 | -0.04 | -0.12 | -0.19 | 0.01 |
| EPS Diluted | -1.46 | -8.22 | -7.99 | -41.01 | -342.14 | -435.59 | 1.83 | -0.56 | -0.53 | -1.48 | -0.30 | -0.29 | -0.24 | -0.24 | -0.04 | -0.12 | -0.19 | 0.01 |
| Weighted Avg Shares Out | 47.42M | 32.27M | 214.91M | 16.91M | 9.68M | 667.69K | 38.32M | 23.25M | 10.75M | 6.41M | 1.35M | 1.34M | 1.32M | 1.32M | 1.23M | 1.20M | 935.16K | 162.85K |
| Weighted Avg Shares Out (Dil) | 47.42M | 32.27M | 214.91M | 16.91M | 9.68M | 667.69K | 39.28M | 23.25M | 10.75M | 6.41M | 1.35M | 1.34M | 1.32M | 1.32M | 1.23M | 1.20M | 935.16K | 162.85K |
7 Struggling Cannabis Stocks to Sell by 2025
Make no mistake: it's still a time when you should be thinking about which cannabis stocks to sell, not which cannabis stocks to buy. Yes, based on the sheer volume of public comments submitted to the Drug Enforcement Administration (...
Aurora Cannabis and Vectura Fertin Pharma, Inc. announce commercial collaboration
Aurora Cannabis and Vectura Fertin Pharma, Inc. announce commercial collaboration Collaboration will initially see launch of a new CBD lozenge from Cogent International, a Vectura Fertin Pharma subsidiary, on Aurora's Canadian medical cannabis patient platform Following successful launch of CBD...
Aurora Cannabis and Vectura Fertin Pharma, Inc. announce commercial collaboration
Collaboration will initially see launch of a new CBD lozenge from Cogent International, a Vectura Fertin Pharma subsidiary, on Aurora's Canadian medical cannabis patient platform Following successful launch of CBD lozenge, the collaboration will explore the potential to launch Vectura Fertin...
Aurora Cannabis Inc. Reminds Shareholders to Vote in Advance of the Proxy Voting Deadline for its 2024 Annual General and Special Meeting of Shareholders
NASDAQ | TSX: ACB Your vote is important no matter how many shares you own. Please vote today.
Aurora Cannabis to Host First Quarter 2025 Investor Conference Call
NASDAQ | TSX: ACB EDMONTON, AB , July 29, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, announced today that it has scheduled a conference call to discuss...
High-Potential Canadian Cannabis Stock to Watch in August 2024
The cannabis industry thrives, with Canada at the forefront of this growth. In August, three Canadian cannabis stocks to watch are SNDL Inc. (SNDL), Village Farms International, Inc. (VFF), and Aurora Cannabis Inc. (ACB). These companies have established significant positions...
3 Canadian Marijuana Stocks For Your August Watchlist
Investing in top marijuana stocks in 2024 can be a bit of a challenge. Sometimes it can be tough knowing which companies to consider and when to take action. For many no matter the sector investing is a skill that...
Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility
Company's Long-Standing Investment in the Region Continues with Enhanced Local Production and Domestic Cultivar Research EDMONTON, AB , July 25, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based global medical cannabis...
Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility
NASDAQ | TSX: ACB Company's Long-Standing Investment in the Region Continues with Enhanced Local Production and Domestic Cultivar Research EDMONTON, AB , July 25, 2024 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based...
1 Stock I Wouldn't Touch With a 10-Foot Pole
Aurora Cannabis has three big strikes against it. The Canada-based cannabis company does have a few good things going for it, though.
Source: https://incomestatements.info
Category: Stock Reports